Navigation Links
diaDexus, Inc. and Living Heart Foundation Offer the PLAC(R) Test to Detect Hidden Risk for Heart Attack and Stroke in Retired NFL Players
Date:9/29/2008

SOUTH SAN FRANCISCO, CALIF., Sept. 29 /PRNewswire/ -- diaDexus, Inc. today announced its partnership with the Living Heart Foundation (LHF), a non-profit organization dedicated to combating cardiovascular disease in current and retired NFL players. The PLAC(R) Test will be included as part of the LHF's cardiovascular risk assessment and disease prevention program designed to identify individuals at elevated risk for suffering a heart attack or stroke.

The PLAC Test is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease and ischemic stroke associated with atherosclerosis. The PLAC Test measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. It is plaque rupture and thrombosis, not stenosis that cause the majority of cardiac events. Clinical research demonstrates that early diagnosis of cardiovascular disease improves the likelihood of preventing these events.

"Traditional risk factors fail to identify many people at risk for developing cardiovascular disease," said Dr. Archie Roberts, founder of the Living Heart Foundation and a former NFL Quarterback. "We are pleased to offer the PLAC Test which provides new information, beyond traditional risk factors, to help identify those individuals with an increased chance of suffering from a cardiovascular event, allowing them to take the necessary steps to improve not only their health, but also their chance of survival."

Dr. Roberts created the LHF to encourage athletes to educate themselves on the importance of early detection and aggressive management of cardiovascular disease through free health clinics and events. The cardiovascular risk assessment and disease prevention programs held around the country will also contribute to research conducted by the LHF exploring the relationship between professional football players and cardiovascular disease.

"I'm thankful the LHF has incorporated the PLAC Test into their health program, as it was an eye opener for my overall health," said David O'Brien, former NFL player for the Minnesota Vikings, New York Giants and St. Louis Cardinals. "I never had heart problems, and my cholesterol was under control so I assumed I was not at risk for a heart attack or stroke. The PLAC Test identified my hidden risk for these events and enabled my doctors to prescribe an aggressive treatment program to lower my risk."

diaDexus is donating the PLAC Test kits for the LHF cardiovascular risk assessment and disease prevention program.

About diaDexus

diaDexus, Inc., a privately held diagnostics company based in South San Francisco, is focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease. For more information, visit http://www.plactest.com or http://www.diaDexus.com.

About the Living Heart Foundation (LHF)

Living Heart Foundation (LHF) is a 501 (c) (3) entity with a national network of hospitals and physicians that unite to fight cardiovascular disease (CVD). The Foundation emphasizes CVD awareness, education, objective testing, early diagnosis and credible research. The 5-year-old ongoing NFL retired player screening/study has a database of over 1,400 former players.


'/>"/>
SOURCE diaDexus, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Touch Bionics acquires LIVINGSKIN
2. UCB Scholarship Program Awards $300,000 to Students Living with Crohns Disease
3. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
4. ATS Medical Expands Open Pivot Heart Valve Offerings
5. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
6. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
7. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
8. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
9. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
10. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
11. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program ... of his grandfather, “Hire for attitude. Train for skill.” , In keeping with this ... Jevohn Miller as a salesman. Zamzow is hoping to replicate the practice throughout the ...
(Date:2/25/2017)... , ... February 25, 2017 , ... ... Verified Clinical Trials in an ongoing effort to create meaningful change by ... and pharmaceutical research with emphasis on consumers and patients’ mental health well-being. , ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Chef Jodi ... wine scene. Making stops in several cities, she gained a number of delicious ... began in Stellenbosch, a town in South Africa’s Western Cape province. It is ...
(Date:2/24/2017)... 2017 Symic Bio, a biopharmaceutical company focused ... of therapeutics, announced today the completion of enrollment for ... disease. The trial will evaluate the safety and efficacy ... reduction of restenosis following angioplasty. "We,re ... SB-030," said Nathan Bachtell , M.D., Chief Medical ...
Breaking Biology Technology:
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
Breaking Biology News(10 mins):